Duke University researchers have devised a promising, potent pain reliever — seemingly without the harmful side effects and ...

Duke scientists may have discovered a game-changing painkiller. SBI-810 is a new non-opioid drug that offers potent pain ...

Eli Lilly will buy privately held SiteOne Therapeutics in a deal worth as much as $1 billion, the companies said on Tuesday, ...

Use of the investigational non-opioid analgesic resiniferatoxin appeared to improve pain control in patients with advanced ...

Eli Lilly has reached a deal to acquire SiteOne Therapeutics that would give it control of a non-opioid pain drug that would ...

The acquisition expands Lilly’s pain pipeline with a slate of drugs targeting ion channel proteins like NaV1.7 and NaV1.8.

a non-opioid treatment, takes a more focused approach, activating only a specific pain-relief pathway that avoids the euphoric "high" linked to addiction. In tests in mice, SBI-810 worked well on ...

Vertex and Eli Lilly are revolutionizing non-opioid pain management with NaV1.8 advancements. See why I'm bullish about LLY ...

While opioids flood multiple cellular pathways indiscriminately, SBI-810, a non-opioid treatment, takes a more focused approach, activating only a specific pain-relief pathway that avoids the ...

Fatal overdoses among US youth from synthetic opioids alone surged from 2018 to 2022, surpassing deaths from polydrug ...

Four months after Vertex Pharmaceuticals Inc.’s U.S. FDA nod for Journavx (suzetrigine) as the first drug targeting NaV1.8 for treating pain, Eli Lilly and Co. is joining the potential competition via ...

Already, the Food and Drug Administration has approved four ... What’s more, the effects of mAbs last longer than opioids and non-steroidal anti-inflammatory drugs (NSAIDs).